Clinical Trial: A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336953) titled 'A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)' on Jan. 04.

Brief Summary: This Phase III randomized trial, evaluates whether adding targeted radiation (SBRT) and an immunotherapy drug (Serplulimab) to standard chemotherapy (GnP) can extend the lives of patients with advanced pancreatic cancer.

Study Start Date: Feb., 2026

Study Type: INTERVENTIONAL

Condition: PDAC - Pancreatic Ductal Adenocarcinoma

Intervention: DRUG: GnP

The GnP regimen is a standard-of-care chemotherapy co...